The new cGMP liquid packaging line allows the use of two fillers (XP and non-XP) working in parallel from process development through to cGMP commercial production and will now offer flexibility to accommodate ethanol and isopropanol-based solutions, aqueous solutions, lotions or suspensions. A new vision system has also been installed for online serialization.
“This investment effectively doubles the liquid packaging capacity and weekly output at the site, while improving production cycle time and providing greater flexibility to customers,” said Maryse Laliberte, VP & General Manager, Cambrex Mirabel. “By operating multiple liquid packaging lines that utilize the same technology, we are able to improve reaction times for our customers’ specific requirements and to support unexpected increases in demand.”
The new cGMP packaging line is linked to the existing storage tank to fill solution and suspension, and to explosion proof ratings tanks to allow for fill solutions containing 100% alcohol or peroxide. The next-generation automatic inline, high precision filler machine will be in operation by June 2019.
Cambrex acquired the 226,000 sq. ft. Montreal facility, formerly part of Halo Pharma, in September 2018. The plant is dedicated to formulation development and finished dosage manufacturing services and can accommodate a wide range of solid and liquid drug product dosage forms, including suspensions and solutions, non-sterile, semi-solids, lotions, creams, ointments and suppositories. It can also support high volume and small batch manufacturing and offers a variety of packaging services for bottles, tubes and cartons.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
Director, Marketing & Communications
Tel: +44 7803 443 155